Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 8/20 | 0.50 |
| ▸ | DRD2 | P14416 | 7/20 | 0.50 |
| ▸ | DRD3 | P35462 | 4/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.41 |
| ▸ | CPT1A | P50416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5647831 | 0.87 | IL2 (0.46) | HTTDRD4DRD2DRD3MEN1 | |
| SCHEMBL3319800 | 0.84 | MAPT (0.52) | HTTUSP30MEN1KMT2A | |
| SCHEMBL3323023 | 0.82 | DRD4 (0.53) | HTTDRD4DRD2DRD3USP30 | |
| SCHEMBL1653301 | 0.79 | HTT (0.79) | HTTDRD4DRD2DRD3USP30 | |
| SCHEMBL3320367 | 0.78 | HRH3 (0.48) | — | |
| SCHEMBL5468773 | 0.76 | DRD4 (0.61) | HTTDRD4DRD2DRD3USP30 | |
| SCHEMBL27812289 | 0.75 | HTT (0.56) | HTTDRD4DRD2DRD3USP30 | |
| SCHEMBL6255441 | 0.74 | DRD4 (0.56) | HTTDRD4DRD2DRD3USP30 | |
| SCHEMBL2374222 | 0.71 | DRD4 (0.67) | DRD4DRD2DRD3USP30MEN1 | |
| SCHEMBL3317713 | 0.71 | KMT2A (0.55) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-7259266-B2 | Benzopyran compounds useful for treating inflammatory conditions | PHARMACIA CORPORATION (US) | 2007-08-21 | — | — | US | disclosed |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-6846825-B1 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | PTGES2, PTGER2, PTGS2 | HTT 3284/4885DRD4 1978/4885DRD2 1689/4885 |
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | HTT 2332/4885DRD4 494/4885DRD2 547/4885 |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | PTGES2, PTGER2, PTGES | HTT 2380/4885DRD4 2462/4885DRD2 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.